News and Announcements
Cellmid Ltd – CEO Interview
- Published November 09, 2012 6:14PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Cellmid (ASX: CDY) develops innovative therapies and diagnostics for cancer, inflammation and heart attack. CDY has the largest global IP portfolio related to growth factor midkine (MK). Its most advanced program is for MK antibodies targeting cancer/inflammation. CDY is also developing MK protein to treat heart attack and other ischemia.
Executive Interviews
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
From Trash to Treasure: Inside Australia’s First Commercial Waste-to-Hydrogen Facility
Greenhill Energy’s pioneering waste-to-hydrogen facility marks a significant step in sustainable energy. This Australian innovation is transforming waste management into clean, valuable hydrogen, presenting investors with a unique, forward-thinking opportunity.
Backed By Leading Investment Groups and Family Offices
